Several studies have explored potential biomarkers, including programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and gene expression signatures; however, none have demonstrated consistent predictive value across clinical trials [2,3,4,5,6,7]. This evidence concerns the gene CD274 and neoplasm.